Reformulary Group

Viewing the opioid crisis through a prescriptive lens


Reformulary Group, a Toronto-based healthcare technology company, analyzed the data of over six million prescription claims from 2013 to 2017, probing the potential contribution of prescription opioids to Canada’s opioid crisis. A critical narrative already widely reported on, MAVERICK needed to compete in a crowded, technical landscape.


Faced with a highly complex and esoteric health report, MAVERICK hijacked the news at every opportunity. Published stories often focused on the use of illicit opioids so we cast a prescriptive lens on the nationwide epidemic, inserting a new framework into the media.

Toronto Star.PNG
Toronto Star 2.PNG
Toronto Star 3.PNG
Toronto Star 4.PNG
Reformulary 1.JPG


Both reactive and proactive media became the cure for Reformulary’s opioid study. MAVERICK tailored the narrative for pitching to verticals including healthcare, HR and policy and developed personal pitches for journalists who had recently reported on the opioid crisis. We also crafted co-authored, regional op-eds on behalf of Helen Stevenson, CEO of Reformulary Group and Mike Boivin, clinical pharmacist consultant and report contributor.


MAVERICK inserted the opioid report and Helen Stevenson as a thought-leader into 56 mainstream news outlets, generating 6,736,500 impressions. Outlets so far include Toronto Star, The Hill Times, Vancouver Magazine, Hamilton Spectator, News1130 and 680NEWS, yet MAVERICK continues to hijack the news and reach out to relevant reporters.


“MAVERICK takes the time to fully understand the context and setting of our business. They are healthcare and business experts who are able to skillfully distill our conversation to its essence and communicate it to a multitude of stakeholders, influencers and gatekeepers. Also, as a small business owner, I really appreciate their agility and willingness to move quickly and seamlessly. They are a joy to work with.”

- Helen Stevenson, Reformulary Group CEO

Helen Stevenson.jpg